請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/15535
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 吳漢忠(Han-Chung Wu) | |
dc.contributor.author | Ya-Hsun Kuo | en |
dc.contributor.author | 郭雅勛 | zh_TW |
dc.date.accessioned | 2021-06-07T17:47:34Z | - |
dc.date.copyright | 2013-09-24 | |
dc.date.issued | 2013 | |
dc.date.submitted | 2013-06-20 | |
dc.identifier.citation | Ahmad, Z.A., Yeap, S.K., Ali, A.M., Ho, W.Y., Alitheen, N.B.M., and Hamid, M. (2012). scFv antibody: principles and clinical application. Clinical and Developmental Immunology 2012.
Akerman, M.E., Chan, W.C., Laakkonen, P., Bhatia, S.N., and Ruoslahti, E. (2002). Nanocrystal targeting in vivo. Proc Natl Acad Sci U S A 99, 12617-12621. Al-Batran, S.E., Bischoff, J., von Minckwitz, G., Atmaca, A., Kleeberg, U., Meuthen, I., Morack, G., Lerbs, W., Hecker, D., Sehouli, J., et al. (2006). The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. Br J Cancer 94, 1615-1620. Al-Lazikani, B., Lesk, A.M., and Chothia, C. (1997). Standard conformations for the canonical structures of immunoglobulins. J Mol Biol 273, 927-948. Altschul, S.F., Madden, T.L., Schaffer, A.A., Zhang, J., Zhang, Z., Miller, W., and Lipman, D.J. (1997). Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25, 3389-3402. Argani, P., Lui, M.Y., Couturier, J., Bouvier, R., Fournet, J.-C., and Ladanyi, M. (2003). A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t (X; 17)(p11. 2; q23). Oncogene 22, 5374-5378. Baneyx, F. (1999). Recombinant protein expression in Escherichia coli. Curr Opin Biotechnol 10, 411-421. Bardeesy, N., and DePinho, R.A. (2002). Pancreatic cancer biology and genetics. Nat Rev Cancer 2, 897-909. Bertin, G., and Averbeck, D. (2006). Cadmium: cellular effects, modifications of biomolecules, modulation of DNA repair and genotoxic consequences (a review). Biochimie 88, 1549-1559. Bonelli, L., Aste, H., Bovo, P., Cavallini, G., Felder, M., Gusmaroli, R., Morandini, E., Ravelli, P., Briglia, R., Lombardo, L., et al. (2003). Exocrine pancreatic cancer, cigarette smoking, and diabetes mellitus: a case-control study in northern Italy. Pancreas 27, 143-149. Bosslet, K., Straub, R., Blumrich, M., Czech, J., Gerken, M., Sperker, B., Kroemer, H.K., Gesson, J.P., Koch, M., and Monneret, C. (1998). Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res 58, 1195-1201. Bramhall, S.R., Rosemurgy, A., Brown, P.D., Bowry, C., and Buckels, J.A. (2001). Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 19, 3447-3455. Bramhall, S.R., Schulz, J., Nemunaitis, J., Brown, P.D., Baillet, M., and Buckels, J.A. (2002). A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87, 161-167. Bridge, J.A., Kanamori, M., Ma, Z., Pickering, D., Hill, D.A., Lydiatt, W., Lui, M.Y., Colleoni, G.W., Antonescu, C.R., Ladanyi, M., et al. (2001). Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol 159, 411-415. Brodin, L., Low, P., and Shupliakov, O. (2000). Sequential steps in clathrin-mediated synaptic vesicle endocytosis. Curr Opin Neurobiol 10, 312-320. Brodsky, F.M., Chen, C.Y., Knuehl, C., Towler, M.C., and Wakeham, D.E. (2001). Biological basket weaving: formation and function of clathrin-coated vesicles. Annu Rev Cell Dev Biol 17, 517-568. Brown, J.M., and Wilson, W.R. (2004). Exploiting tumour hypoxia in cancer treatment. Nature Reviews Cancer 4, 437-447. Cai, W., and Chen, X. (2008). Preparation of peptide-conjugated quantum dots for tumor vasculature-targeted imaging. Nature Protocols 3, 89-96. Carmeliet, P., and Jain, R.K. (2000). Angiogenesis in cancer and other diseases. Nature 407, 249-257. Carreno, S., Engqvist-Goldstein, A.E., Zhang, C.X., McDonald, K.L., and Drubin, D.G. (2004). Actin dynamics coupled to clathrin-coated vesicle formation at the trans-Golgi network. J Cell Biol 165, 781-788. Cerqueira, N.M., Fernandes, P.A., and Ramos, M.J. (2007). Understanding ribonucleotide reductase inactivation by gemcitabine. Chemistry 13, 8507-8515. Chang, D.K., Chiu, C.Y., Kuo, S.Y., Lin, W.C., Lo, A., Wang, Y.P., Li, P.C., and Wu, H.C. (2009). Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors. J Biol Chem 284, 12905-12916. Chanjuan Shi, R.H.H., and Alison P. Klein (2009). Familial Pancreatic Cancer. Arch Pathol Lab Med 133, 365-374. Cho, K., Wang, X., Nie, S., and Shin, D.M. (2008). Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 14, 1310-1316. Conroy, T., Desseigne, F., Ychou, M., Bouche, O., Guimbaud, R., Becouarn, Y., Adenis, A., Raoul, J.L., Gourgou-Bourgade, S., de la Fouchardiere, C., et al. (2011). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364, 1817-1825. Conway, E.M., Collen, D., and Carmeliet, P. (2001). Molecular mechanisms of blood vessel growth. Cardiovasc Res 49, 507-521. Dahan, M., Levi, S., Luccardini, C., Rostaing, P., Riveau, B., and Triller, A. (2003). Diffusion dynamics of glycine receptors revealed by single-quantum dot tracking. Science Signaling 302, 442. Davis, M.E. (2008). Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature Reviews Drug Discovery 7, 771-782. Deborde, S., Perret, E., Gravotta, D., Deora, A., Salvarezza, S., Schreiner, R., and Rodriguez-Boulan, E. (2008). Clathrin is a key regulator of basolateral polarity. Nature 452, 719-723. Di Tommaso, L., Destro, A., Fabbris, V., Spagnuolo, G., Laura Fracanzani, A., Fargion, S., Maggioni, M., Patriarca, C., Maria Macchi, R., Quagliuolo, M., et al. (2011). Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma. Hepatology 53, 1549-1557. Drummond, D.C., Meyer, O., Hong, K., Kirpotin, D.B., and Papahadjopoulos, D. (1999). Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 51, 691-743. Dubertret, B., Skourides, P., Norris, D.J., Noireaux, V., Brivanlou, A.H., and Libchaber, A. (2002). In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science 298, 1759-1762. Duggan, S.T., and Keating, G.M. (2011). Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma. Drugs 71, 2531-2558. Dumonceau, J.M., and Vonlaufen, A. (2007). Pancreatic endoscopic retrograde cholangiopancreatography (ERCP). Endoscopy 39, 124-130. Eckerich, C., Zapf, S., Fillbrandt, R., Loges, S., Westphal, M., and Lamszus, K. (2007). Hypoxia can induce c‐Met expression in glioma cells and enhance SF/HGF‐induced cell migration. Int J Cancer 121, 276-283. Edge, S.B., and American Joint Committee on Cancer. (2010). AJCC cancer staging manual, 7th edn (New York ; London: Springer). Enari, M., Ohmori, K., Kitabayashi, I., and Taya, Y. (2006). Requirement of clathrin heavy chain for p53-mediated transcription. Genes Dev 20, 1087-1099. Escobar, G.A., McIntyre, R.C., Jr., Moore, E.E., Gamboni-Robertson, F., and Banerjee, A. (2006). Clathrin heavy chain is required for TNF-induced inflammatory signaling. Surgery 140, 268-272. Fjallskog, M.L., Lejonklou, M.H., Oberg, K.E., Eriksson, B.K., and Janson, E.T. (2003). Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 9, 1469-1473. Folkman, J. (2002). Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29, 15-18. Fu, W., Jiang, Q., and Zhang, C. (2011). Novel functions of endocytic player clathrin in mitosis. Cell Res 21, 1655-1661. Fusaroli, P., and Eloubeidi, M.A. (2012). Pancreatic cancer: Image enhancement by endoscopic ultrasonography-elastography. Nat Rev Gastroenterol Hepatol 9, 623-624. G. Kloppel, E.S., D.S. Longnecker, C. Capella, and L.H. Sobin (1996). HistologicaTyping of Tumours of the Exocrine Pancreas, second edn (Springer). Gao, X., Cui, Y., Levenson, R.M., Chung, L.W., and Nie, S. (2004). In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 22, 969-976. Griffiths, A.D., and Duncan, A.R. (1998). Strategies for selection of antibodies by phage display. Curr Opin Biotechnol 9, 102-108. Gyorffy, B., Lanczky, A., Eklund, A.C., Denkert, C., Budczies, J., Li, Q., and Szallasi, Z. (2010). An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 123, 725-731. Gyorffy, B., Benke, Z., Lanczky, A., Balazs, B., Szallasi, Z., Timar, J., and Schafer, R. (2012). RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data. Breast Cancer Res Treat 132, 1025-1034. Harding, H.P., Zhang, Y., and Ron, D. (1999). Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 397, 271-274. Hashizume, H., Baluk, P., Morikawa, S., McLean, J.W., Thurston, G., Roberge, S., Jain, R.K., and McDonald, D.M. (2000). Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156, 1363-1380. Heinemann, V., and Boeck, S. (2008). Perioperative management of pancreatic cancer. Ann Oncol 19 Suppl 7, vii273-278. Heldin, C.H., Rubin, K., Pietras, K., and Ostman, A. (2004). High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 4, 806-813. Hermann, P.C., Huber, S.L., Herrler, T., Aicher, A., Ellwart, J.W., Guba, M., Bruns, C.J., and Heeschen, C. (2007). Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 313-323. Hidalgo, M. (2010). Pancreatic cancer. N Engl J Med 362, 1605-1617. Hong, S.M., Park, J.Y., Hruban, R.H., and Goggins, M. (2011). Molecular signatures of pancreatic cancer. Arch Pathol Lab Med 135, 716-727. Hruban, R.H., Takaori, K., Klimstra, D.S., Adsay, N.V., Albores-Saavedra, J., Biankin, A.V., Biankin, S.A., Compton, C., Fukushima, N., Furukawa, T., et al. (2004). An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. The American journal of surgical pathology 28, 977-987. Imai, K., and Takaoka, A. (2006). Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 6, 714-727. Immordino, M.L., Dosio, F., and Cattel, L. (2006). Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 1, 297-315. Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J.M., Lane, W.S., and Kaelin Jr, W.G. (2001). HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science Signaling 292, 464. Jain, R.K. (1996). 1995 Whitaker Lecture: delivery of molecules, particles, and cells to solid tumors. Ann Biomed Eng 24, 457-473. Jiao, L., Mitrou, P.N., Reedy, J., Graubard, B.I., Hollenbeck, A.R., Schatzkin, A., and Stolzenberg-Solomon, R. (2009). A combined healthy lifestyle score and risk of pancreatic cancer in a large cohort study. Arch Intern Med 169, 764-770. Jones, S., Zhang, X., Parsons, D.W., Lin, J.C., Leary, R.J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008). Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806. Karmazanovsky, G., Fedorov, V., Kubyshkin, V., and Kotchatkov, A. (2005). Pancreatic head cancer: accuracy of CT in determination of resectability. Abdom Imaging 30, 488-500. Kelley, R.K., and Ko, A.H. (2008). Erlotinib in the treatment of advanced pancreatic cancer. Biologics 2, 83-95. Kennel, S.J., Woodward, J.D., Rondinone, A.J., Wall, J., Huang, Y., and Mirzadeh, S. (2008). The fate of MAb-targeted Cd (125m) Te/ZnS nanoparticles in vivo. Nucl Med Biol 35, 501-514. Khazaeli, M., Conry, R.M., and LoBuglio, A.F. (1994). Human immune response to monoclonal antibodies. J Immunother 15, 42-52. Kim, M.L., Sorg, I., and Arrieumerlou, C. (2011). Endocytosis-independent function of clathrin heavy chain in the control of basal NF-kappaB activation. PLoS One 6, e17158. Kindler, H.L., Niedzwiecki, D., Hollis, D., Sutherland, S., Schrag, D., Hurwitz, H., Innocenti, F., Mulcahy, M.F., O'Reilly, E., Wozniak, T.F., et al. (2010). Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 28, 3617-3622. Kirchhausen, T., Harrison, S.C., Chow, E.P., Mattaliano, R.J., Ramachandran, K.L., Smart, J., and Brosius, J. (1987). Clathrin heavy chain: molecular cloning and complete primary structure. Proc Natl Acad Sci U S A 84, 8805-8809. Klein, A.P. (2013). Identifying people at a high risk of developing pancreatic cancer. Nat Rev Cancer 13, 66-74. Knaust, R.K., and Nordlund, P. (2001). Screening for soluble expression of recombinant proteins in a 96-well format. Anal Biochem 297, 79-85. Kojima, K., McQueen, T., Chen, Y., Jacamo, R., Konopleva, M., Shinojima, N., Shpall, E., Huang, X., and Andreeff, M. (2011). p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α–mediated down-regulation of CXCL12. Blood 118, 4431-4439. Koritzinsky, M., Magagnin, M.G., van den Beucken, T., Seigneuric, R., Savelkouls, K., Dostie, J., Pyronnet, S., Kaufman, R.J., Weppler, S.A., and Voncken, J.W. (2006). Gene expression during acute and prolonged hypoxia is regulated by distinct mechanisms of translational control. EMBO J 25, 1114-1125. Lee, T.Y., Lin, C.T., Kuo, S.Y., Chang, D.K., and Wu, H.C. (2007). Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery. Cancer Res 67, 10958-10965. Lee, T.Y., Wu, H.C., Tseng, Y.L., and Lin, C.T. (2004). A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery. Cancer Res 64, 8002-8008. Li, C., Heidt, D.G., Dalerba, P., Burant, C.F., Zhang, L., Adsay, V., Wicha, M., Clarke, M.F., and Simeone, D.M. (2007). Identification of pancreatic cancer stem cells. Cancer Res 67, 1030-1037. Li, C., Wu, J.J., Hynes, M., Dosch, J., Sarkar, B., Welling, T.H., Pasca di Magliano, M., and Simeone, D.M. (2011). c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 141, 2218-2227 e2215. Lo, A., Lin, C.T., and Wu, H.C. (2008). Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol Cancer Ther 7, 579-589. Longley, D.B., Harkin, D.P., and Johnston, P.G. (2003). 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3, 330-338. Loukanov, A.R., Dushkin, C.D., Papazova, K.I., Kirov, A.V., Abrashev, M.V., and Adachi, E. (2004). Photoluminescence depending on the ZnS shell thickness of CdS/ZnS core-shell semiconductor nanoparticles. Colloids and Surfaces A: Physicochemical and Engineering Aspects 245, 9-14. Lowenfels, A.B., Maisonneuve, P., Cavallini, G., Ammann, R.W., Lankisch, P.G., Andersen, J.R., Dimagno, E.P., Andren-Sandberg, A., and Domellof, L. (1993). Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 328, 1433-1437. Lu, R.M., Chang, Y.L., Chen, M.S., and Wu, H.C. (2011). Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials 32, 3265-3274. Lucenteforte, E., La Vecchia, C., Silverman, D., Petersen, G.M., Bracci, P.M., Ji, B.T., Bosetti, C., Li, D., Gallinger, S., Miller, A.B., et al. (2012). Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol 23, 374-382. Luo, J., Iwasaki, M., Inoue, M., Sasazuki, S., Otani, T., Ye, W., and Tsugane, S. (2007). Body mass index, physical activity and the risk of pancreatic cancer in relation to smoking status and history of diabetes: a large-scale population-based cohort study in Japan--the JPHC study. Cancer Causes Control 18, 603-612. Maitra, A., Adsay, N.V., Argani, P., Iacobuzio-Donahue, C., De Marzo, A., Cameron, J.L., Yeo, C.J., and Hruban, R.H. (2003). Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol 16, 902-912. Matsumura, Y., Gotoh, M., Muro, K., Yamada, Y., Shirao, K., Shimada, Y., Okuwa, M., Matsumoto, S., Miyata, Y., Ohkura, H., et al. (2004). Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol 15, 517-525. McCafferty, J., Griffiths, A.D., Winter, G., and Chiswell, D.J. (1990). Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348, 552-554. McMahon, H.T., and Boucrot, E. (2011). Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat Rev Mol Cell Biol 12, 517-533. Miyoshi, A., Kitajima, Y., Ide, T., Ohtaka, K., Nagasawa, H., Uto, Y., Hori, H., and Miyazaki, K. (2006). Hypoxia accelerates cancer invasion of hepatoma cells by upregulating MMP expression in an HIF-1alpha-independent manner. Int J Oncol 29, 1533-1539. Monti, E., and Gariboldi, M. (2011). HIF-1 as a target for cancer chemotherapy, chemosensitization and chemoprevention. Current molecular pharmacology 4, 62. Moore, M.J., Goldstein, D., Hamm, J., Figer, A., Hecht, J.R., Gallinger, S., Au, H.J., Murawa, P., Walde, D., Wolff, R.A., et al. (2007). Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25, 1960-1966. Moore, M.J., Hamm, J., Dancey, J., Eisenberg, P.D., Dagenais, M., Fields, A., Hagan, K., Greenberg, B., Colwell, B., Zee, B., et al. (2003). Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21, 3296-3302. Murr, M.M., Sarr, M.G., Oishi, A.J., and van Heerden, J.A. (1994). Pancreatic cancer. CA Cancer J Clin 44, 304-318. Neoptolemos, J.P., Stocken, D.D., Bassi, C., Ghaneh, P., Cunningham, D., Goldstein, D., Padbury, R., Moore, M.J., Gallinger, S., Mariette, C., et al. (2010). Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304, 1073-1081. Niemeyer, C.M. (2001). Nanoparticles, proteins, and nucleic acids: biotechnology meets materials science. Angewandte Chemie International Edition 40, 4128-4158. Ohata, H., Ota, N., Shirouzu, M., Yokoyama, S., Yokota, J., Taya, Y., and Enari, M. (2009). Identification of a function-specific mutation of clathrin heavy chain (CHC) required for p53 transactivation. J Mol Biol 394, 460-471. Ohmori, K., Endo, Y., Yoshida, Y., Ohata, H., Taya, Y., and Enari, M. (2008). Monomeric but not trimeric clathrin heavy chain regulates p53-mediated transcription. Oncogene 27, 2215-2227. Pandol, S., Gukovskaya, A., Edderkoui, M., Dawson, D., Eibl, G., and Lugea, A. (2012). Epidemiology, risk factors, and the promotion of pancreatic cancer: role of the stellate cell. J Gastroenterol Hepatol 27, 127-134. Pelley, J.L., Daar, A.S., and Saner, M.A. (2009). State of academic knowledge on toxicity and biological fate of quantum dots. Toxicol Sci 112, 276-296. Philip, P.A., Benedetti, J., Corless, C.L., Wong, R., O'Reilly, E.M., Flynn, P.J., Rowland, K.M., Atkins, J.N., Mirtsching, B.C., Rivkin, S.E., et al. (2010). Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 28, 3605-3610. Pylayeva-Gupta, Y., Lee, K.E., Hajdu, C.H., Miller, G., and Bar-Sagi, D. (2012). Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21, 836-847. Raimondi, S., Maisonneuve, P., and Lowenfels, A.B. (2009). Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 6, 699-708. Saisho, H., and Yamaguchi, T. (2004). Diagnostic imaging for pancreatic cancer: computed tomography, magnetic resonance imaging, and positron emission tomography. Pancreas 28, 273-278. Sapra, P., and Allen, T.M. (2002). Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res 62, 7190-7194. Seimiya, M., Tomonaga, T., Matsushita, K., Sunaga, M., Oh-Ishi, M., Kodera, Y., Maeda, T., Takano, S., Togawa, A., Yoshitomi, H., et al. (2008). Identification of novel immunohistochemical tumor markers for primary hepatocellular carcinoma; clathrin heavy chain and formiminotransferase cyclodeaminase. Hepatology 48, 519-530. Semenza, G.L., and Wang, G.L. (1992). A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12, 5447-5454. Shaib, Y., Davila, J., Naumann, C., and El-Serag, H. (2007). The impact of curative intent surgery on the survival of pancreatic cancer patients: a U.S. Population-based study. Am J Gastroenterol 102, 1377-1382. Siegel, R., Naishadham, D., and Jemal, A. (2012). Cancer statistics, 2012. CA Cancer J Clin 62, 10-29. Society, A.C. (2012). Cancer Facts & Figures 2012 (Atlanta: American Cancer Society). Sorkin, A., and von Zastrow, M. (2009). Endocytosis and signalling: intertwining molecular networks. Nature reviews Molecular cell biology 10, 609-622. Spano, J.P., Chodkiewicz, C., Maurel, J., Wong, R., Wasan, H., Barone, C., Letourneau, R., Bajetta, E., Pithavala, Y., Bycott, P., et al. (2008). Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 371, 2101-2108. Tobita, K., Kijima, H., Dowaki, S., Kashiwagi, H., Ohtani, Y., Oida, Y., Yamazaki, H., Nakamura, M., Ueyama, Y., Tanaka, M., et al. (2003). Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. Int J Mol Med 11, 305-309. Tung, K.H., Lin, C.W., Kuo, C.C., Li, L.T., Kuo, Y.H., and Wu, H.C. (2013). CHC promotes tumor growth and angiogenesis through regulation of HIF-1alpha and VEGF signaling. Cancer Lett 331, 58-67. Van Cutsem, E., van de Velde, H., Karasek, P., Oettle, H., Vervenne, W.L., Szawlowski, A., Schoffski, P., Post, S., Verslype, C., Neumann, H., et al. (2004). Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22, 1430-1438. Von Hoff DD, E.T., Arena FP, et al (2012). Paper presented at: 2013 Gastrointestinal Cancers Symposium. Von Hoff, D.D., Ramanathan, R.K., Borad, M.J., Laheru, D.A., Smith, L.S., Wood, T.E., Korn, R.L., Desai, N., Trieu, V., Iglesias, J.L., et al. (2011). Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 29, 4548-4554. Wilentz, R.E., Iacobuzio-Donahue, C.A., Argani, P., McCarthy, D.M., Parsons, J.L., Yeo, C.J., Kern, S.E., and Hruban, R.H. (2000). Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 60, 2002-2006. Wollert, T., and Hurley, J.H. (2010). Molecular mechanism of multivesicular body biogenesis by ESCRT complexes. Nature 464, 864-869. Wu, H.C., and Chang, D.K. (2010). Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy. J Oncol 2010, 723798. Xia, Y., Choi, H.K., and Lee, K. (2012). Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur J Med Chem 49, 24-40. Yang, R.S., Chang, L.W., Wu, J.-P., Tsai, M.-H., Wang, H.-J., Kuo, Y.-C., Yeh, T.-K., Yang, C.S., and Lin, P. (2007). Persistent tissue kinetics and redistribution of nanoparticles, quantum dot 705, in mice: ICP-MS quantitative assessment. Environ Health Perspect 115, 1339. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/15535 | - |
dc.description.abstract | 胰臟癌的死亡率高居全球所有癌症的第五名,由於早期診斷上的困難,也缺乏有效的治療方式,導致胰臟癌是個致死率高、極度惡性的癌症,因此針對胰臟癌發展新的治療與診斷策略實屬當務之急。過去的研究顯示,網格重鏈蛋白(CHC)在胰臟癌細胞中呈現高度表現,並且扮演了促進腫瘤生長和腫瘤血管新生的角色。在本篇研究當中,我們更進一步發現,在內源性CHC表現量較低的癌細胞中,以轉染方式送進質體使CHC過度表現,會增進癌細胞移動以及轉移的能力。另一方面,研究也顯示在缺氧狀態下,細胞膜上的CHC會和缺氧誘發因子-1α (HIF-1α)在細胞質有直接的交互作用。基於以上的發現,我們希望發展以CHC為標的之藥物傳輸系統。由於先前的研究中,我們以融合瘤技術得到了一株能專一性辨認CHC蛋白的鼠源單株抗體;在本篇研究,我們將這株鼠源單株抗體的重鏈變異區與輕鏈變異區以一段短胜肽連結成單鏈抗體(scFv),保留其互補決定區域(CDR),而將抗體架構區域修飾成人源化序列,完成的人源化單鏈抗體命名為hPa65-2 scFv。我們發現hPa65-2 scFv不僅對胰臟癌細胞有極佳的鍵結能力,也能高度被細胞進行內化作用。我們更進一步發現將hPa65-2 scFv與微脂體進行鍵結,可以促進微脂體專一性辨認癌細胞,以及進一步進行內化作用。於藥物傳輸系統的應用上,可以發現帶有抗癌藥物的微脂體在鍵結了hPa65-2 scFv之後,對於人類胰臟癌細胞異體移植的免疫缺陷型小鼠有較好的療效。另一方面,在造影醫學的應用上,我們將鍵結有hPa65-2 scFv的量子點與沒有鍵結的量子點分別以靜脈注射的方式打入小鼠體內,進行活體螢光影響觀察,發現將hPa65-2 scFv鍵結上量子點能增加量子點辨認腫瘤細胞的能力,也提高量子點累積於腫瘤與正常器官的比值。綜合以上結果,hPa65-2 scFv這株專一性辨認CHC蛋白的單鏈抗體,不僅能應用於藥物傳輸系統,增加化療藥物的專一性,提升其治療效果,還可以結合造影系統,以協助胰臟癌患者的早期診斷。 | zh_TW |
dc.description.abstract | Pancreatic adenocarcinoma is a highly malignant cancer with poor prognosis due to lack of effective therapies and diagnosis. Therefore, development of new strategies to improve treatment and diagnosis is urgently desirable. We have previously demonstrated that clathrin heavy chain (CHC) protein promotes tumor growth and angiogenesis in pancreatic cancer. In this study, we further found that CHC protein overexpression significantly increased cell migration and invasion ability. In the hypoxic state, CHC would bind with HIF-1α protein in cytoplasm. In order to develop CHC-targeted drug delivery for cancer therapy, we engineered the humanized scFv (single-chain fragment variable) antibody against CHC, which was derived from anti-CHC monoclonal antibody Pa65-2 and was named hPa65-2 scFv. We have verified that hPa65-2 scFv not only retained the ability to bind to pancreatic cancer cells efficiently, but it also exhibited high level of endocytosis activity. Conjugation of hPa65-2 scFv with liposomal SRB was able to improve binding and internalization efficiency of liposomes to tumor cells. We also found that hPa65-2 scFv-conjugated liposomes can enhance delivery of doxorubicin into cancer cells and increase its cytotoxic effect. In a tumor xenograft model, hPa65-2 scFv-conjugated liposomes were found to improve therapeutic efficacy of a chemotherapeutic drug. In order to develop targeting imaging in tumor-bearing mice, hPa65-2 scFv were conjugated with quantum dots. In vivo fluorescence imaging showed that scFv-conjugated quantum dots increased tumor uptake and improved tumor-normal tissue ratio compared to non-targeting quantum dots. We conclude that anti-CHC scFv has significant potential in targeted drug delivery and imaging for pancreatic cancer. | en |
dc.description.provenance | Made available in DSpace on 2021-06-07T17:47:34Z (GMT). No. of bitstreams: 1 ntu-102-R00450001-1.pdf: 4305244 bytes, checksum: 468a3110167e240aaf7f87a538803e3c (MD5) Previous issue date: 2013 | en |
dc.description.tableofcontents | 誌謝 i
中文摘要 ii Abstract iii Contents iv Content of figures and tables vi List of abbreviations vii Introduction 1 1.1 Epidemiology of pancreatic cancer 1 1.2 Pathogenesis of pancreatic adenocarcinoma 2 1.3 Pancreatic cancer therapy 4 1.4 Targeted therapy of pancreatic cancer 7 1.5 Diagnosis of pancreatic cancer 10 1.6 Drug delivery system 12 1.7 Quantum dots for nanoparticle diagnosis 14 1.8 Single-chain variable fragment (scFv) 15 1.9 Hypoxia inducible factor- 1 α 18 1.10 Clathrin heavy chain (CHC) 20 1.11 Specific aim 23 Material and method 25 2.1 Cell lines and culture condition 25 2.2 Generation of anti-CHC monoclonal antibodies 25 2.3 Generation of stable clones overexpressing CHC 26 2.4 Cell proliferation assay 27 2.5 Cell migration and invasion 28 2.6 Enzyme-linked immunosorbent assay (ELISA) 29 2.7 Flow cytometry analysis 30 2.8 Western blot analysis 30 2.9 Expression and purification of soluble scFv 31 2.10 Endocytosis ability of anti-CHC antibody and hPa65-2 scFv 33 2.11 Construction of hPa65-2 scFv- conjugated liposomal SRB (hPa65-2 scFv-SRB) or liposomal doxorubicin 33 2.12 Construction of hPa65-2 scFv-conjugated quantum dots 35 2.13 Binding affinity analysis of liposome conjugates hPa65-2 scFv 36 2.14 Internalization ability of liposome conjugates hPa65-2 scFv 36 2.15 Endocytosis of liposome conjugates hPa65-2 scFv 36 2.16 Xenograft model for study of scFv-targeted therapy 37 2.17 In vivo diagnosis analysis of hPa65-2 scFv-QD 38 2.18 Immunofluorescence assay of frozen tissue section 38 2.19 Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) Assay 39 2.20 Hypoxia induction 39 2.21 In silico analysis 40 2.22 Statistical analysis 40 Results 42 3.1 Elevation of CHC expression in human cancer cells 42 3.2 CHC participates in the migration and invasion ability of cancer cells 42 3.3 Characterization of binding and internalization of anti-CHC in MIA-PaCa-2 cells 44 3.4 Binding and internalization activity of hPa65-2 scFv 45 3.5 hPa65-2 scFv enhances the binding and internalization of LiposomalSRB 47 3.6 hPa65-2 scFv enhances liposomal drug binding, intracellular delivery and cytotoxicity 49 3.7 Therapeutic efficacy of hPa65-2 scFv-LD in human pancreatic cancer xenograft 50 3.8 Imaging of hPa65-2 scFv-QD 51 3.9 Interaction between CHC and HIF-1α 52 3.10 Trapping of HIF-1α in cytoplasm by hPa65-2 scFv-QD 53 Discussion 55 References 79 | |
dc.language.iso | en | |
dc.title | 發展對抗CHC之人源化抗體運用於胰臟癌之治療與造影 | zh_TW |
dc.title | Development of anti-CHC humanized antibody for targeted drug delivery and imaging of pancreatic cancer | en |
dc.type | Thesis | |
dc.date.schoolyear | 101-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 李文山(Wen-Shan Li),呂仁(Joyce Jean Lu) | |
dc.subject.keyword | 胰臟癌,CHC,HIF-1α,單鏈抗體,藥物傳輸系統,微脂體, | zh_TW |
dc.subject.keyword | pancreatic cancer,clathrin heavy chain,HIF-1α,scFv,drug delivery systems,immunoliposome, | en |
dc.relation.page | 91 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2013-06-21 | |
dc.contributor.author-college | 牙醫專業學院 | zh_TW |
dc.contributor.author-dept | 口腔生物科學研究所 | zh_TW |
顯示於系所單位: | 口腔生物科學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-102-1.pdf 目前未授權公開取用 | 4.2 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。